Slides on a New Era in Treating Spinal Muscular Atrophy

How can you improve the screening and diagnosis of spinal muscular atrophy (SMA) and what treatments options are available to discuss with families? View, download, and share these expert slides on SMA.
Samiah Al-Zaidy, MD
Vanessa Battista, MS, RN, CPNP
Nancy L. Kuntz, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.10 MB
Released: September 3, 2020

Acknowledgements

Provided by Clinical Care Options, in collaboration with the National Association of Pediatric Nurse Practitioners

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

 

5 Hanover Square, Suite 1401
New York, NY 10004
Phone: 877-662-7627
Email: info@napnap.org

Supported by educational grants from
Biogen
Genentech, a member of the Roche Group

Related Content

From Clinical Care Options (CCO) and Anli Liu, MD, expert insight on new epilepsy data from AAN 2021: MONEAD pregnancy, cenobamate, cannabidiol, soticlestat

Anli A. Liu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: May 28, 2021 Expired: May 27, 2022

From Clinical Care Options (CCO), new data from AAN 2021 on cenobamate, lamotrigine, carbamazepine for uncontrolled focal seizures from the C021 study

Released: April 26, 2021

From Clinical Care Options (CCO), new data from AAN 2021 on CBD add-on therapy in treatment-resistant epilepsy

Released: April 26, 2021

Expert commentary from CCO on key clinical information about each FDA-approved agent for treating spinal muscular atrophy (SMA)

Nancy L. Kuntz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 23, 2020 Expired: October 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue